Topiramate Extended Release Generic

Quote


















Hopefully we will got more insight on the expected impact Qudexy will have on us either positive or negative at the Q1 POA. Also it would be great if they would review the emerging competition we have next year for both epilepsy and migraine at the Q1 POA. This would include the oral MABS set to arrive in 2020 and also SK's blockbuster destined partial/generalized epilepsy med coming out early next year.
 






We will not hear anything in regards to competition. The Supernus way is “don’t talk about them and doctors won’t use it...” or downplay new drugs launching. Trokendixr has maybe a year left on it. By that time there will be multiple generics plus all of the cgrp products coming in 2020. Need to pray for 812
 






anonymous said:
Hopefully we will got more insight on the expected impact Qudexy will have on us either positive or negative at the Q1 POA. Also it would be great if they would review the emerging competition we have next year for both epilepsy and migraine at the Q1 POA. This would include the oral MABS set to arrive in 2020 and also SK's blockbuster destined partial/generalized epilepsy med coming out early next year.
Click to expand...

Easy with the “blockbuster destined” talk. We heard the same thing about 810...
 






























anonymous said:
Anybody heard anything about the new generic from your offices? I have not
Click to expand...

What would make you think our offices are going to take the time to mention that now? Also what would make you think Zydus would be stupid enough to launch it now?

This has to be someone from corporate fishing with the field for intel. If you are coming to CP for competitive knowledge you are far less prepared for this thing going generic than I could have ever imagined.
 






anonymous said:
What would make you think our offices are going to take the time to mention that now? Also what would make you think Zydus would be stupid enough to launch it now?

This has to be someone from corporate fishing with the field for intel. If you are coming to CP for competitive knowledge you are far less prepared for this thing going generic than I could have ever imagined.
Click to expand...


Why wouldn’t Zydus launch? Not like this has to be detailed. All they have to do is list it, contract and let the payers switch Rxs behind the scenes.
 






anonymous said:
Why wouldn’t Zydus launch? Not like this has to be detailed. All they have to do is list it, contract and let the payers switch Rxs behind the scenes.
Click to expand...

Zydus will not target payers but will work directly with pharmacies to switch patients. Once the pharmacist recommends a cheaper alternative to patients I'd say payers wont object. This will be a nightmare.
 


















anonymous said:
Why will the second generic be substitutable at the pharmacy if the first wasn’t?
Click to expand...

This is correct. They can’t substitute Trokendi XR at the pharmacy with new generic. Patient would have to contact provider who would have to write new Rx for topiramate ER which most know isn’t any better than IR.
 






anonymous said:
This is correct. They can’t substitute Trokendi XR at the pharmacy with new generic. Patient would have to contact provider who would have to write new Rx for topiramate ER which most know isn’t any better than IR.
Click to expand...

For a patient to get TXR they have to ST the IR. Now they are going to have to ST this generic as well.
 






This is how things will look over the next few months. A new patient goes to the pharmacy with a script of TXR, the pharmacy will try to run the script and one of two scenarios will happen it will either be covered or not. If it's covered the patient will walk out of the pharmacy with TXR.

If it's not covered or requires a PA which we know happens more often than not, then the pharmacists will recommend this new generic as a replacement.

This is very easy to predict. Next topic please.
 






anonymous said:
This is how things will look over the next few months. A new patient goes to the pharmacy with a script of TXR, the pharmacy will try to run the script and one of two scenarios will happen it will either be covered or not. If it's covered the patient will walk out of the pharmacy with TXR.

If it's not covered or requires a PA which we know happens more often than not, then the pharmacists will recommend this new generic as a replacement.

This is very easy to predict. Next topic please.
Click to expand...

Riddle this for me. Do we already have a problem with the pharmacies recommending the current generic? It is priced less than 1/2 of TXR.
 






anonymous said:
Riddle this for me. Do we already have a problem with the pharmacies recommending the current generic? It is priced less than 1/2 of TXR.
Click to expand...

The good news is Zydus's generic isn't listed as available on goodrx yet. As far as you wanting me to take the bait you are laying out I'll pass. I have no desire to argue with you on a topic I already know what the outcome will be.

I will be more than happy to revisit this topic with you 90 days from now. I will put a reminder in my calendar book why don't you do the same.
 






Top Bottom
Back
Quote